EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch

PartnershipsemaglutidePositive

AI Analysis

Summary

BD and EMS announced a collaboration to expand access to semaglutide, a GLP-1 therapy, in Brazil by combining pharmaceutical leadership with advanced drug delivery technology for metabolic disease patients.

Importance:5/10

Sentiment:

0.50

GLP-1 therapiesBrazilcollaborationdrug deliverysemaglutidemarket access

Related Companies

$BDX

Read the original article

Published by PR Newswire Biotech on July 29, 2026 10:54 AM

Read Original